Human Papillomaviruses As Therapeutic Targets in Human Cancer
Human Papillomaviruses As Therapeutic Targets in Human Cancer
复制标题
DOI：
10.1200/jco.2010.28.2186
复制
发表时间：
2011-05-01
影响因子：
45.3
通讯作者：
Muenger, Karl
中科院分区：
文献类型：
--
作者：
Hellner, Karin;Muenger, Karl
宫颈癌几乎普遍与高危型人乳头瘤病毒（HPV）感染相关，是全球女性癌症死亡的主要原因。HPV癌蛋白有助于癌症的发生和发展，并且它们的表达对于维持转化状态是必要的。事实上，启动致癌性损伤，感染高危型HPV和病毒癌蛋白表达，是常见的几乎所有宫颈癌提供了独特的机会，预防，早期发现和治疗。通过引入预防性疫苗来预防特定高危HPV的传播，已经实现了预防的潜力。然而，鉴于这些疫苗没有治疗效果，HPV相关的宫颈癌在最初感染后数年甚至数十年后出现，估计在2040年之前HPV相关肿瘤不会有可测量的下降。从现在到2040年，仅宫颈癌就将在超过375，000名美国妇女中被诊断出来。其他HPV相关的肛门生殖器和头颈部癌症预计将在这段时间内折磨另外70万男性和女性。因此，对抗高危HPV相关疾病的治疗努力仍然至关重要。
Cervical carcinomas are almost universally associated with high-risk human papillomavirus (HPV) infections, and are a leading cause of cancer death in women worldwide. HPV oncoproteins contribute to cancer initiation and progression and their expression is necessary for the maintenance of the transformed state. The fact that the initiating oncogenic insult, infection with a high-risk HPV and viral oncoprotein expression, is common to almost all cervical cancers offers unique opportunities for prevention, early detection, and therapy. The potential for prevention has been realized by introduction of prophylactic vaccines that are to prevent transmission of specific high-risk HPVs. Given, however, that these vaccines have no therapeutic efficacy and HPV-associated cervical cancers arise years if not decades after the initial infection, it has been estimated that there will be no measurable decline of HPV-associated tumors before 2040. Cervical cancer alone will be diagnosed in more than 375,000 US women between now and 2040. Other HPV-associated anogenital and head and neck cancers are predicted to afflict another 700,000 men and women over this time period. Hence, therapeutic efforts to combat high-risk HPV-associated disease remain of critical importance.